Innoviva, Inc.
INVAInnoviva, Inc. is a diversified biopharmaceutical company that operates a dual-model business consisting of a high-margin respiratory royalty portfolio and a wholly owned specialty therapeutics platform.
Earnings
Next report
Nov 4, 2026 (in a month)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Innoviva, Inc. is a diversified biopharmaceutical company that operates a dual-model business consisting of a high-margin respiratory royalty portfolio and a wholly owned specialty therapeutics platform. The company focuses on the development and commercialization of critical care and infectious disease treatments for the hospital setting, while leveraging long-term royalty streams from partnered respiratory assets. Innoviva actively manages a portfolio of strategic healthcare investments to drive long-term shareholder value through capital allocation in areas of significant unmet medical need.
Innoviva holds a leading position in the niche critical care and infectious disease market while maintaining a significant royalty interest in established global respiratory franchises.
FAQ
- What is Innoviva, Inc.'s market cap?
- Innoviva, Inc. (INVA) has a market capitalization of $1.5B and trades on NASDAQ.
- What is Innoviva, Inc.'s revenue and profitability?
- Innoviva, Inc. generated $440.0M in trailing twelve-month revenue with net income of $357.2M, representing a net margin of 81.2%. Gross margin stands at 72.2%, with free cash flow of $189.4M. The latest reported period is Q2 2026.
- Who are Innoviva, Inc.'s competitors?
- Innoviva, Inc.'s key competitors include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.
- Who does Innoviva, Inc. partner with?
- Innoviva, Inc.'s notable partners include GSK, Basilea Pharmaceutica Ltd, Everest Medicines Limited, and others.
- What subsidiaries does Innoviva, Inc. have?
- Innoviva, Inc.'s subsidiaries include Entasis Therapeutics, La Jolla Pharmaceutical, Tetraphase Pharmaceuticals, Inc., and others.
- Where is Innoviva, Inc. headquartered?
- Innoviva, Inc. is headquartered in United States of America and employs approximately 112 people. It has been publicly traded since 2004.
